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Abstract
Purpose Patient-reported fatigue after robotic-assisted radical prostatectomy (RARP) has not been characterised to date. Fatigue
after other prostate cancer (PCa) treatments is known to impact on patient-reported quality of life. The aim of this study was to
characterise fatigue, physical activity levels and cardiovascular status post-RARP.
Methods Between October 2016 andMarch 2017, men post-RARP or on androgen deprivation therapy (ADT) were invited into
the study. Participants were asked to complete the Brief Fatigue Inventory (BFI) and Stage of Change and Scottish Physical
Activity Questionnaires (SPAQ) over a 2-week period. Outcome measures were patient-reported fatigue, physical activity levels
and the 10-year risk of cardiovascular disease (Q-Risk). Data were analysed in SPSS.
Results 96/117 (82%) men approached consented to participate; of these, 62/96 (65%) returned complete questionnaire data
(RARP n = 42, ADT n = 20). All men reported fatigue with 9/42 (21%) post-RARP reporting clinically significant fatigue.
Physical activity did not correlate with fatigue. On average, both groups were overweight (BMI 27.0 ± 3.9 kg/m2 and 27.8 ±
12.3 kg/m2 for RARP and ADT, respectively) and the post-RARP group had an 18.1% ± 7.4% Q-Risk2 score.
Conclusions A proportion of men is at increased risk of cardiovascular disease within 10 years post-RARP and have substantial
levels of fatigue; therefore, clinicians should consider including these factors when counselling patients about RARP.
Additionally, men post-RARP did not meet the recommended guidelines for resistance-based exercise. Future research is needed
to establish whether interventions including resistance-based exercise can improve health and fatigue levels in this population.
Keywords Prostate cancer . Prostatectomy . Fatigue . Physical activity
Introduction
Radical prostatectomy is an accepted curative treatment op-
tion for men with clinically localised significant prostate can-
cer (PCa) with greater than 10 years of life expectancy and the
ability to perform activities of daily living [1]. Robotic-
assisted radical prostatectomy (RARP) is now the most
prevalent modality for surgical removal of the prostate for
PCa in the UK [2].
RARP has been demonstrated to be associated with lower
blood loss and decreased hospital staywhen compared to open
radical prostatectomy [3]. Although commonly assumed that
men undergoing RARP are fit and return to their pre-operative
physical activity levels after surgery, there is little published
data to substantiate this assumption. The prevalence of fatigue
and post-operative physical fitness in men who have under-
gone RARP is largely unknown with few studies performed to
date have explored cancer-related fatigue post-RARP. What
data there is suggests that fatigue is present in PCa patients but
is affected by treatment modality and the time period over
which fatigue is assessed; however, it has been previously
reported that approximately 14% of patients who have under-
gone radical prostatectomy experience fatigue [4, 5]. Fatigue
in cancer patients and survivors has been associated with re-
duced physical activity levels [6], potentially adversely
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affecting cardiovascular risk profile and recovery to full func-
tional fitness after RARP.
To our knowledge, no study has explored the association
between self-reported physical activity, fatigue and comorbid-
ities in men who have undergone RARP. The aim of this pilot
study was to characterise fatigue, physical activity levels and
cardiovascular status, over a 2-week period, in men after
RARP and establish whether this is a substantial problem,
which future intervention studies should address.
Methods
Design
A cross-sectional questionnaire study was administered to
men who had undergone RARP and men treated with ADT
for PCa. Men on continuousmedical ADT, a treatment strong-
ly associated with a number of side effects that impact quality
of life including significant fatigue [7], were purposely used as
a comparative populationwith which to relate the morbidity of
RARP. The study was approved by the South East Scotland
NHS Research Ethics Committee. Data from the ADT cohort
of men is presented as a comparative control population.
This study was conducted at Newcastle upon Tyne
Hospitals NHS Foundation Trust which is a tertiary referral
centre serving a population of 1.2 million people. RARP was
performed by three experienced surgeons at the institution
over the study period.
Participants
Men were eligible to participate in the study if they: (1) had
histologically confirmed PCa, (2) were at least 8 weeks after
their treatment for PCa with either RARP or after initiation of
ADT, and (3) were able to provide consent and satisfactorily
complete written questionnaires. All eligible patients attend-
ing outpatient’s clinics were approached. Men receiving any
other treatment for PCa were excluded from the study.
Study outcome data
Consenting men were asked to provide demographic informa-
tion including current health status, average weekly alcohol
intake and smoking status, and stature and body mass were
measured. They were then invited to complete a questionnaire
booklet containing validated questionnaires prospectively
over a 2-week period (see further details below) and return
the booklet in a prepaid stamp addressed envelope.
Questionnaire score calculations were performed in accor-
dance with published questionnaire protocols. Likewise, miss-
ing data were treated in accordance with the questionnaire
protocols. The questionnaires included are detailed below.
Comorbidity and cardiovascular status
Charlson Comorbidity Index was calculated using informa-
tion provided on stature, body mass and medical history [8,
9]. The risk of suffering a heart attack or stroke within the next
10 years was calculated using the validated objective measure:
Q-Risk2 [10]. Q-Risk2 score is calculated from patient med-
ical record data including family history, age, gender, ethnic-
ity, socio-economic status, and selected physiological mea-
surements, and can be categorised as <10% (low), 10%-20%
(medium) or > 20% (high) [11]. Q-Risk2 was specifically
used in this study, because in addition to being the NICE
recommended formal risk assessment tool for CVD, it is also
an accepted aid to clinical decision-making regarding how
intensively to intervene to improve health in patients with
CVD [12].
Scottish Physical Activity Questionnaire
The Scottish Physical Activity Questionnaire (SPAQ) was
completed at the end of both weeks as a recall questionnaire
and has good reliability (Cronbach’s alpha = 0.998) [13]. This
questionnaire assesses moderate to vigorous physical activity
(MVPA) over the previous 7 days. The questionnaire includes
sections for both leisure time and occupational physical activ-
ity with each section containing questions on general activity
such as walking, stair climbing and manual labour [13]. The
average weekly total MVPAwas calculated in addition to the
mean total for each individual exercise component.
Brief Fatigue Inventory
The BFI was completed at the end of each day for all 14 days
of the data collection period to rapidly assess fatigue in cancer
patients and is correlated with other validated fatigue ques-
tionnaires [14–16] and has good reliability (Cronbach’s al-
pha = 0.95) [16]. The BFI consists of three questions assessing
fatigue severity and six questions assessing the interference of
fatigue with the patient’s mood and social/physical function-
ing with all answers being on a 0–10 scale. A global fatigue
score was obtained for weeks 1 and 2 by averaging all the
items on the BFI and as an average of the whole 2-week period
[16]. Clinically significant fatigue is defined as a global fa-
tigue score > 3 [5, 17].
Stage of Change Questionnaire
The Stage of Change Questionnaire was administered once at
the start of the 2-week study period to assess patient’s attitudes
towards exercise behaviour change and has acceptable reli-
ability (Cronbach’s alpha = 0.63) [18]. Participants answered
‘yes’ or ‘no’ to four statements to assess each individual’s
stage of behaviour change [6]. The stages are categorised as
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follows: stage 1—pre-contemplation, stage 2—contempla-
tion, stage 3—preparation, stage 4—action and, and stage
5—maintenance.
Statistical analysis
All returned surveys were included in the analysis, even if
some sections were incomplete. Consequently, the number
of total responses for each survey item varied because of
missing data. Analyses were conducted using IBM SPSS
Statistics Version 22 (IBM United Kingdom Limited,
Hampshire, UK).
Normality was assessed using the Shapiro–Wilk and, if
data was not normally distributed, transformations were con-
ducted using common logarithms or square root. To assess the
associations of the outcomes with self-reported total PA levels
(SPAQ), Pearson correlations and Spearman’s rank were
employed. Independent samples t tests were used to examine
differences between the two treatment groups with p < 0.05
chosen as the accepted level of significance.
Results
Participants
In total, 148 menwere approached to take part in the study and
96 men consented to participate in the study; of these, 62/96
(65%) patients returned postal questionnaires. Table 1
illustrates the demographic of the cohort. The patients
approached were on average 11.7 months after RARP and
22.1 months after the initiation of ADT. The RARP cohort
comprised 42/62 responses; of these, 57% and 14%were clas-
sified as overweight and obese, respectively.
Cardiovascular status
Charlson Comorbidity Indexcalculations indicated that there
was no significant difference in estimated 10-year survival
after RARP (87.3% ± 12.2%) or ADT (80.5% ± 18.7%),
t(27.2) = 1.5, p = 0.2. Q-Risk2 scores indicated that there
was no significant difference in 10-year risk of suffering a
heart attack or stroke between men post-RARP (18.1% ±
7.4%) and after initiation of ADT (22.4% ± 10.8%),
t(28.4) = −1.6, p = 0.12.
Physical activity
The levels of reported PA did not differ over the 2-week period
between the two treatment groups (RARP total average
mins = 658.1 ± 337.6 versus ADT total average mins =
631.9 ± 318.5, t(59) = 0.3, p = 0.8). Age, body mass, BMI
and BFI scores were not associated with the total amount of
PA performed in either treatment group (Table 2).
Approximately 50% of all PA reported in both groups in-
volved walking (e.g. walking to the shops/work, stair walk-
ing). Activities included in the ‘other’ category included yoga
(1/42 post-RARP, 1/20 ADT), bowls (1/42 post-RARP) and
rambling (2/42 post-RARP, 1/20 ADT). A breakdown of the
amount of physical activity undertaken is illustrated in
Table 3.
Fatigue
All patients were experiencing fatigue over the 2-week study
period; the majority of fatigue reported was mild-moderate in
severity and of borderline clinical significance. The mean
Table 1 Patient demographics
RARP (n = 42) ADT (n = 20)
Age (years) 63.8 ± 6.4 67.3 ± 9.0
Body mass (kg) 86.7 ± 13.4 86.4 ± 12.3
Stature (cm) 180 ± 0.07 176 ± 0.07
Body mass index (kg/m2) 27.0 ± 3.9 27.8 ± 12.3
Drink alcohol n (%) 38 (90.5) 18 (80.0)
Months since treatment mean (range) 11.7 (2–115) 22.1 (2–120)
Pre-RARP PSA 10.05 ± 6.3
Pathological Gleason Score (n)
GS 6 2
GS 3 + 4 25
GS 4+ 3 7
GS ≥ 8 8
Pathological tumour stage (n)
PT2 24
PT3a 13
PT3b 5
Data are presented as mean ± standard deviation unless stated otherwise
RARP robot-assisted radical prostatectomy, ADT androgen deprivation
therapy, PSA prostate specific androgen
Table 2 Correlation matrix between physical activity and demographic
factors, comorbidities, stage of change and fatigue
Physical activityª
RARP ADT
Age − 0.1 − 0.14
Body mass − 0.02 − 0.31
Body mass index 0.1 − 0.09
Stage of change 0.36b 0.15
Brief Fatigue Inventory − 0.09 0.09
ªTotal physical activity in minutes averaged over the 2-week study period
b Correlation is significant at the 0.05 level
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severity of fatigue was significantly less over the 2-week study
period in the RARP (1.6 ± 1.7) than in the ADT group (2.6 ±
1.8), t(60) = − 2.628, p = 0.011 (Fig. 1). However, 9/42
(21.4%) patients’ post-RARP and 6/20 (30%) ADT patients
reported clinically significant fatigue. There was no associa-
tion between fatigue and the amount of self-reported PA
(Table 2).
Stage of change
The majority of patients in both treatment groups reported
being in the maintenance stage of change (Table 4). The main-
tenance phase is where individuals have made specific modi-
fications to their exercise behaviour; however, it requires a
conscious effort to in order to maintain it. The stage of change
outcomes positively correlated with the amount of PA under-
taken in the RARP treatment group; this is shown in Table 2.
Discussion
This is the first study to our knowledge to quantitatively ex-
plore cardiovascular risk, fatigue and physical activity, in men
who have undergone RARP as a PCa treatment. Our study
found that a substantial proportion of men post-RARP is at
increased risk of suffering a cardiovascular related event with-
in 10–15 years of their surgery and may suffer from clinically
significant fatigue. Importantly, this study demonstrated that
these findings were present in men appearing to meet the UK
public health guidance of undertaking at least 150 min a week
of moderate to vigorous aerobic physical activity. There was
no significant difference between the cardiovascular risks
found in men post-RARP and those on ADT in this study.
The present study identified that the Q-Risk2 score of the
RARP cohort indicated that they were at a 18% greater risk of
suffering a heart attack or stroke within the next 10 years.
Whilst cardiovascular risk status has been studied extensively
in patients receiving ADT [19–22], there are no studies, as far
as the authors are aware to date, which have characterised the
cardiovascular risk status of RARP patients. The largest most
contemporary study by Wilt et al. [23] gives a signal as to
mortality risk from causes other than PCa in a radical prosta-
tectomy population. During a median follow-up of period of
10 years, 171/281 of the radical prostatectomy group died, and
of these deaths, 74% (127/171) were not due to PCa [23].
Whilst it cannot be inferred that cardiovascular disease was
the cause of all of these deaths due to other factors such as old
age, this analysis combined with our study findings indicate
potentially more can be done to improve the health of patients
undergoing RARP. The Q-Risk2 calculator aids clinical
decision-making about how intensively to recommend life-
style interventions and lipid-lowering medications to patients
with significant cardiovascular risks during patient-centred
consultations [10]. The results of our study showed that our
RARP cohort was at a 3% elevated risk of cardiovascular
disease when compared to moderately active males of a sim-
ilar age [24]. This finding, where it to be replicated in future
studies, supports the view that men after RARP should at the
very least be informed of their risk which could increase their
compliance when offered lifestyle interventions to improve
their cardiovascular health [25, 26].
Cancer-related fatigue has previously been reported as a
side effect of PCa treatment in up to 80% of men [27–30].
Few studies have investigated levels of fatigue in men who
have exclusively undergone RARP for PCa; however, much
work has been conducted in men receiving ADT and
Fig. 1 Brief Fatigue Inventory scores presented as a global score (range
of scores 1–6) for RARP and ADT over the 2-week study period
Table 4 Stage of change scores for both treatment groups
RARP (n = 42) ADT (n = 20)
Stage of change (number of patients)
Stage 1—pre-contemplation 0 0
Stage 2—contemplation 1 3
Stage 3—preparation 0 1
Stage 4—action 5 3
Stage 5—maintenance 36 13
Table 3 Self-reported MVPA over the 2-week period
RARP ADT
Total (mins) 658.1 ± 337.6 631.9 ± 318.5
Walking (mins) 341.4 ± 245.5 319.5 ± 251.4
Manual labour (mins) 125.4 ± 168.3 92.3 ± 158.2
Active housework (mins) 57.6 ± 79.6 82.4 ± 89.4
Dancing (mins) 3.2 ± 11.3 0.63 ± 2.8
Sport/Leisure activities (mins) 92.3 ± 178.5 126.4 ± 209.4
Other activities (mins) 40.4 ± 100.2 6.3 ± 22.3
Data are presented as mean ± standard deviation
Two RARP participants did not provide physical activity data for week 1
or week 2
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radiotherapy. Storey et al. [5] performed a cross-sectional
questionnaire study of recurrence free survivors who had un-
dergone open radical prostatectomy utilising the BFI.
Clinically relevant fatigue was identified in 22% (29/133) of
men undergoing radical prostatectomy, whereas in their con-
trol non-cancer population, the incidence of clinically relevant
fatigue was 16% (10/63) at a median follow-up of 56 months
after treatment. Within their radical prostatectomy cohort me-
dian age 72, coexisting depression had the strongest indepen-
dent association with fatigue. Storey et al. [5] did not examine
PA levels within their cohort. Cancer-related fatigue has been
acknowledged to be debilitating and to significantly impact on
quality of life [31]. We have shown that after RARP in a
contemporary younger population, similar to Storey et al.,
clinically relevant fatigue is reported by 20% of men at a mean
follow-up of 11.7 months. This finding might be considered
unexpected but highlights that post-treatment fatigue should
be discussed with patients when they are counselled for
RARP. All patients included in our study underwent holistic
needs assessment after treatment and received targeted sup-
port if required as part of routine care from a survivorship
nurse specialist [32, 33]. We have previously demonstrated
that men in our institution who undergo RARP experience
an unchanged overall quality of life [32]; therefore, it is prob-
able that the clinically relevant fatigue identified in this study
is unlikely to have resulted from psychological factors.
As far as the authors are aware, this is the first examination
of PA sub-classifications undertaken in a contemporary pop-
ulation of men who have undergone RARP. Our study found
patient-reported levels of PA after RARP which met current
UK public health guidelines within the RARP cohort despite a
high proportion of our patients having a high body mass in-
dex. We demonstrated that PA levels did not correlate with
fatigue levels suggesting that fatigue levels may not be a bar-
rier to the amount of PA undertaken within this population.
Although public health guideline levels of aerobic PA were
met, we identified that post-RARP patients did not achieve the
recommended weekly amount of resistance exercise [34],
with none of the patients reporting completing any resistance
exercise. This important finding highlights a potential area of
unmet need in the post-RARP population. Resistance exercise
has previously been examined in other PCa treatment groups,
both epidemiologically and during interventional studies
which found resistance exercise to be safe in the population,
alongside mitigating fatigue and generating longer-term im-
provements in quality of life, strength, triglycerides and body
fat when compared to aerobic exercise [28, 35, 36]. The po-
tential benefits of resistance exercise in relation to cardiomet-
abolic risk profile were highlighted in a recent meta-analysis
[37]. Although loss of skeletal muscle mass has been widely
reported in PCa patients undergoing ADT [38–40] and many
studies have investigated the impact of resistance exercise
training programmes [35, 39, 41], much fewer studies have
assessed changes in skeletal muscle characteristics after
RARP. There is a need for future research to address this
evidence gap, and extending the provision of structured exer-
cise interventions (including resistance exercise) to this popu-
lation may be warranted. Such interventions could have a
positive impact on fatigue in men recovering from RARP, as
demonstrated previously in fatigued PCa patients receiving
ADT [29].
This study’s findings add quantitative depth to recent qual-
itative work performed by Sutton et al. [42] and Hackshaw-
McGeagh et al. [43] identifying patients’ priorities. These
studies showed that men undergoing RARP would value PA
and dietary advice from their healthcare professional and
would prefer to receive this at an early stage. In addition, they
provided evidence that men undergoing RARP are willing to
change their behaviour to improve their health, but they wish
to be supported by their healthcare professional team to do so.
Undergoing RARP is potentially a ‘teachable moment,’ and
we have demonstrated that this population is at risk of both
cardiovascular events and fatigue. Qualitative research shows
men are receptive to health behaviour change [42–44], and
such initiatives targeted at this population could have much
potential to improve men’s overall health.
Our study supports consideration of further targeted re-
search into strategies aimed at improving the health of men
who have undergone RARP. Feasibility to recruit patients and
compliance with completing study questionnaires has been
demonstrated, in addition to the ability to discriminate the
health status and behaviours of the RARP population. The
present study has limitations.Whilst the patient-reported ques-
tionnaire data showed that all men appeared to meet UK guid-
ance physical activity levels, the authors did not expect this
finding. Additionally, we identified that the SPAQ does not
allow for the separation of exercise at varying intensities, and
therefore, potential over reporting of the amount of MVPA
may take place. For example, within the walking category,
some low intensity physical activity may have been included
despite the instructions stating otherwise. We believe that our
findings justify the inclusion of activity trackers used in par-
allel with patient-reported activity questionnaires in future
study protocols to strengthen validity of activity outcome re-
sults. Our study did not investigate participants for sleep dis-
orders. Although non-restorative sleep and fatigue are differ-
ent entities, we acknowledge symptoms described by patients
with each of these conditions may be similar and this should
be investigated in future studies with a measure of sleep qual-
ity used alongside fatigue questionnaires [45]. In this study,
we did not use a group of healthy menwithout cancer who had
not undergone surgery as a comparator group and accept that
this might be considered as a limitation. Patient and Public
Involvement was integral to the design of this study. Prostate
cancer patients felt that it was assumed that, because they were
undergoing RARP, they were fit and that there was a lack of
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recommendations and guidance regarding fatigue, and health
and lifestyle improvements they could make after RARP that
should be addressed. This study was pragmatically designed
in response to specific feedback from the Newcastle upon
Tyne Patient and Public Involvement Group who felt that
the comparator should be what they considered the most mor-
bid prostate cancer treatment continuous ADT on the basis
that, if similar morbidities were demonstrated, this would re-
inforce the need for targeted interventions in men after RARP.
We acknowledge however that cardiovascular risk and fatigue
will be present in the general healthy population. Finally, al-
though the numbers included in this study were small, it has
identified the need for further study in this population of men
and informed the sample size calculation required for further
work in this area. In order to conduct a fully powered study
using the reported fatigue effect size from this pilot study
(Cohen’s d = 0.57), the minimum total sample size to achieve
80% power (α = 0.05) was determined as n = 100 patients (50
patients in each group) would be needed to detect differences
in fatigue between the two groups [46].
Conclusion
Our study has shown that some men post-RARP are at in-
creased risk of clinically significant consequences from car-
diovascular disease within 10 years of their surgery and do
suffer with clinically significant levels of fatigue. Clinicians
should consider including these factors in the discussion when
counselling patients about RARP. We have shown that men
after RARP appear to meet the recommended guidelines for
aerobic physical activity but do not meet them for resistance-
based exercise. Future research is needed to establish whether
exercise interventions can improve health and fatigue levels in
this population.
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